Physiology · PeptideU · 7 min read

Sotatercept: Physiology and What Research Reports

The short answer

Sotatercept is an engineered fusion protein that acts as an activin signalling inhibitor, built from the extracellular domain of the activin receptor type IIA joined to an antibody Fc region. It is not made by the body; it is manufactured and was studied by subcutaneous injection in pulmonary arterial hypertension trials. Published randomised trials reported changes in pulmonary vascular resistance, six-minute walk distance and clinical worsening events, alongside reported adverse events such as epistaxis, telangiectasia, raised haemoglobin and thrombocytopenia.

Sotatercept is one of the few large engineered proteins that moved from haematology research into cardiopulmonary medicine, and it appears in peptide and protein-therapeutic reading lists because of how it works rather than what it treats. This page summarises what the published literature describes, in third person, without instructions of any kind.

What Sotatercept Is

Sotatercept is a recombinant fusion protein rather than a short synthetic peptide. A 2024 drug profile described it as an activin signalling inhibitor composed of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the Fc portion of human IgG1, developed for pulmonary arterial hypertension (PAH) and administered by subcutaneous injection (PMID 38904927). Because the receptor domain is presented outside the cell membrane, the molecule behaves as a soluble decoy or "ligand trap": circulating ligands that would normally dock onto ActRIIA on a cell surface bind the fusion protein instead.

It is therefore not produced anywhere in the human body. What is produced in the body are its targets — members of the TGF-β superfamily including activins and growth differentiation factors, which are expressed across vascular, skeletal, muscular and haematopoietic tissue. The same 2024 profile noted that sotatercept received its first approval in the United States in 2024 for adults with PAH (WHO Group 1) to increase exercise capacity, improve WHO functional class and reduce the risk of clinical worsening events (PMID 38904927).

The signalling balance it is designed to shift

In pulmonary vascular biology, two branches of TGF-β superfamily signalling are usually contrasted: a pro-proliferative activin/ActRII arm and a growth-restraining bone morphogenetic protein (BMPR2) arm. Loss of BMPR2 function is a well-known feature of heritable PAH. The rationale described in the phase 2 report was that trapping activin-family ligands would restore balance between these arms in the pulmonary vasculature, and researchers tested that hypothesis by measuring pulmonary vascular resistance as the primary endpoint (PMID 33789009).

How It Is Studied and Measured

Sotatercept is not assessed with a simple blood level in routine practice. The literature instead used physiological and functional readouts:

Right-heart catheterisation for pulmonary vascular resistance (PVR) and mean pulmonary arterial pressure — the primary measure in the phase 2 study (PMID 33789009).
Six-minute walk distance (6MWD) — the primary endpoint of the phase 3 STELLAR trial (PMID 36877098).
Echocardiographic and haemodynamic indices of right ventricular function, examined in a dedicated STELLAR analysis of haemodynamics and right heart function (PMID 37696565).
Event-driven endpoints such as death, lung transplantation or hospitalisation, used in a trial of patients at high risk for death (PMID 40167274).
Haematology panels, because ActRIIA ligand trapping affects erythropoiesis and platelets — increases in haemoglobin and cases of thrombocytopenia were reported in the phase 2 study (PMID 33789009).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

What the Clinical Literature Reports

Phase 2 (PULSAR)

The phase 2 trial administered sotatercept at 0.3 mg/kg or 0.7 mg/kg subcutaneously every 21 days alongside background therapy for 24 weeks, and researchers reported reductions in pulmonary vascular resistance compared with placebo at both dose levels (PMID 33789009). An open-label extension of that study followed participants beyond the controlled period and reported that improvements in haemodynamic and functional measures were maintained over longer exposure (PMID 36041750).

Phase 3 (STELLAR)

In the phase 3 trial, adults with PAH already on background therapy received sotatercept or placebo every three weeks for 24 weeks, and the study reported a median change from baseline in six-minute walk distance of 34.4 m with sotatercept versus 1.0 m with placebo, a median difference of 40.8 m (PMID 36877098). A secondary analysis of the same trial reported improvements in haemodynamic parameters and measures of right heart function relative to placebo (PMID 37696565).

Higher-risk and earlier-disease populations

A subsequent trial enrolled patients at high risk for death and used a composite of death, lung transplantation and PAH-related hospitalisation, where researchers reported fewer composite events with sotatercept than placebo (PMID 40167274). A further trial examined patients within the first year after PAH diagnosis and reported outcomes for clinical worsening in that earlier-treatment setting (PMID 41025556).

Long-term follow-up

Interim results from the SOTERIA long-term follow-up study reported continued safety and efficacy observations in participants who rolled over from earlier sotatercept trials (PMID 39978862).

Study type	Main measure reported	Reference
Phase 2, placebo-controlled	Pulmonary vascular resistance at 24 weeks	PMID 33789009
Phase 3, placebo-controlled	Six-minute walk distance at 24 weeks	PMID 36877098
Event-driven, high-risk patients	Death, transplantation or hospitalisation	PMID 40167274
Open-label extension / follow-up	Durability over longer exposure	PMID 36041750

Preclinical and Case-Level Reports

Animal work has explored contexts beyond Group 1 PAH: a study in experimental left heart failure reported that a sotatercept analogue improved cardiopulmonary remodelling and pulmonary hypertension in that model (PMID 36910526). At the case level, a published report described weaning of prostacyclin infusion therapy in a patient with PAH after sotatercept was added (PMID 40933796), and a separate report described sotatercept use in patients with Eisenmenger syndrome (PMID 41815805). Single cases and animal models describe observations; they do not establish general effects.

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

Sotatercept Adverse Events: What Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

In the phase 3 trial, the study reported epistaxis, dizziness, telangiectasia, increased haemoglobin levels, thrombocytopenia and increased blood pressure more frequently with sotatercept than with placebo (PMID 36877098). The phase 2 trial reported thrombocytopenia and increased haemoglobin among the adverse events observed with sotatercept (PMID 33789009). Longer-term follow-up in the SOTERIA interim analysis reported safety observations across extended exposure (PMID 39978862). A 2025 postmarketing pharmacovigilance analysis examined real-world reports and described serious events not listed in the product labelling, illustrating how signals can emerge after approval (PMID 41033707).

Why the Term Comes Up in Peptide Reading

Sotatercept is frequently used as a teaching example of a ligand trap — a protein that works by removing signalling molecules from circulation rather than by activating a receptor. That mechanism sits at the opposite end of the spectrum from small receptor-agonist peptides, and the contrast helps explain why molecule size, Fc fusion, half-life and route of administration differ so much across the field. It is a prescription biologic approved for a specific, serious cardiopulmonary indication (PMID 38904927), not a research-only compound, and the literature on it is entirely clinical-trial based.

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

Limits of the Evidence

Most controlled data come from 24-week trials in patients already receiving background PAH therapy (PMID 36877098). Longer-term and real-world information is still accumulating through follow-up studies and pharmacovigilance reporting (PMID 39978862, PMID 41033707). Findings in one disease population do not transfer automatically to another.

References

Frequently asked questions

What is sotatercept?▾

Sotatercept is an engineered fusion protein — the extracellular domain of the activin receptor type IIA joined to an IgG1 Fc region — described in the literature as an activin signalling inhibitor given by subcutaneous injection and first approved in 2024 for pulmonary arterial hypertension in adults (PMID 38904927). It acts as a decoy that binds circulating activin-family ligands rather than stimulating a receptor.

What adverse events have studies reported?▾

The phase 3 trial reported epistaxis, dizziness, telangiectasia, increased haemoglobin, thrombocytopenia and increased blood pressure more often with sotatercept than placebo (PMID 36877098). The earlier phase 2 study also reported thrombocytopenia and increased haemoglobin (PMID 33789009). A 2025 postmarketing analysis examined real-world reports and described serious events not listed in labelling (PMID 41033707).

Is sotatercept a peptide?▾

Not in the usual sense. It is a large recombinant Fc-fusion protein rather than a short synthetic peptide chain, described as an activin signalling inhibitor built from a receptor domain and an antibody fragment (PMID 38904927). It appears in peptide education mainly as a contrasting example of a ligand-trap mechanism versus small receptor-agonist peptides.

What did the phase 3 STELLAR trial report?▾

In adults with pulmonary arterial hypertension already on background therapy, the study reported a median change from baseline in six-minute walk distance at 24 weeks of 34.4 m with sotatercept versus 1.0 m with placebo, a median difference of 40.8 m (PMID 36877098). A separate analysis of the same trial reported improvements in haemodynamics and right heart function measures (PMID 37696565).

How was sotatercept dosed in the published trials?▾

The phase 2 trial administered sotatercept at 0.3 mg/kg or 0.7 mg/kg subcutaneously every 21 days for 24 weeks alongside background therapy, and researchers reported reductions in pulmonary vascular resistance versus placebo at both levels (PMID 33789009). These figures describe what that trial protocol used; they are not guidance for any individual and are prescriber-determined.

Has sotatercept been studied beyond standard PAH populations?▾

Yes. One trial enrolled patients at high risk for death using a composite of death, lung transplantation and hospitalisation (PMID 40167274), and another studied patients within the first year after diagnosis (PMID 41025556). Case-level reports have described use in Eisenmenger syndrome (PMID 41815805) and weaning of prostacyclin infusion therapy (PMID 40933796).

What is known about long-term use?▾

Interim results from the SOTERIA long-term follow-up study reported safety and efficacy observations in participants continuing from earlier sotatercept trials (PMID 39978862), and an open-label extension of the phase 2 study reported that improvements were maintained over longer exposure (PMID 36041750). Long-term and real-world evidence remains less mature than the 24-week randomised data.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes — records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium — $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free

References

Keep learning

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.